IL6 and breast cancer: These findings indicate that IL-6 serum level peaks are a highly time-dependent early biomarker, as corroborated by Westbury et al. [38] which showed no significant differences in IL-6 serum levels in BC patients at 2 or 5 years post-RT as assessed during the monitoring of RT-induced fibrosis.